SILVIO O. CONTE DIGESTIVE DISEASES RESEARCH CORE CENTERS
RELEASE DATE: May 7, 2003
RFA: DK-03-016
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
(http://www.niddk.nih.gov/)
CATALOG OF FEDERAL DOMESTIC ASSISTANCE NUMBER: 93.848
LETTER OF INTENT RECEIPT DATE: October 16, 2003
APPLICATION RECEIPT DATE: November 13, 2003
THIS RFA CONTAINS THE FOLLOWING INFORMATION
o Purpose of this RFA
o Research Objectives
o Mechanism(s) of Support
o Funds Available
o Eligible Institutions
o Individuals Eligible to Become Principal Investigators
o Special Requirements
o Where to Send Inquiries
o Letter of Intent
o Submitting an Application
o Peer Review Process
o Review Criteria
o Receipt and Review Schedule
o Award Criteria
o Required Federal Citations
PURPOSE OF THIS RFA
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
invite applications for Silvio O. Conte Digestive Diseases Research Core
Center grants. Five competing Digestive Diseases Research Core Center Grants
(P30) will be awarded in fiscal year 2005.
The Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs) are
part of an integrated program of digestive diseases-related research support
provided by the NIDDK. The Centers currently funded in this program have
provided a focus for increasing collaboration and improving the cost-
effectiveness of supported research among groups of successful investigators
at institutions with an established, comprehensive digestive diseases
research base.
RESEARCH OBJECTIVES
The objective of the Core Centers is to bring together investigators from
relevant disciplines to enhance and extend the effectiveness of research
related to digestive diseases and their complications. A Core Center must be
an identifiable unit within a single university medical center or a
consortium of cooperating institutions, including an affiliated university.
The overall goal of the Core Center is to bring together clinical and basic
science investigators in a manner that will enrich the effectiveness of
digestive diseases research. An existing program of excellence in biomedical
research in the area of digestive diseases and disorders is required. This
research must be in the form of NIH funded research projects, program
projects, or other peer-reviewed research that is already funded at the time
of submission of a Center grant application. Close cooperation,
communication, and collaboration among all involved personnel of various
professional disciplines are the ultimate objectives.
The Core Center must have a central focus of research investigation. The
central focus must be a digestive disease, group of diseases or functional
studies relating to digestive diseases; at least half of the research must
relate to this central focus. Examples of a gastrointestinal disease-related
central focus of research investigation include (but are not restricted to)
inflammatory bowel disease, functional bowel disorders, pancreatic disease,
liver disease, pediatric gastrointestinal disease, and AIDS in
gastrointestinal disease. Examples of functional studies as the central
focus include (but are not restricted to) gastrointestinal motility,
gastrointestinal hormones, or gene therapy for digestive diseases.
Applicants should consult with NIDDK staff concerning plans for the
development of the Center and the organization of the application.
Silvio O. Conte Digestive Diseases Research Core Centers are based on the
core concept. Three to six cores are usually included in a Center. Cores
are defined as shared resources that enhance productivity or in other ways
benefit a group of investigators working in a center to accomplish the stated
goals of the Center. Examples of such resources include imaging resources,
transgenic animal facilities, and membrane preparation facilities.
Centers are encouraged to include a clinical component. This clinical
component can exist as a stand-alone component or as a part of another core
such as the Administrative core. Besides leading to a better understanding
of disease etiology and natural history of disease, clinical components might
provide biostatistics support; enhance clinical study design; foster
collaboration among researchers; aid in recruitment of subjects for clinical
studies; support epidemiological studies in areas of digestive diseases; or
provide modest funding for tissue, DNA, or serum storage. In addition, a
clinical component may more effectively address NIH policies concerning
issues of women, children, and ethnic minority population participation in
clinical studies.
Two other types of activities also may be supported with Center funding: a
Pilot and Feasibility (P/F) program and an Enrichment program. The P/F
program provides modest support for new initiatives or feasibility research
studies. This program is directed at new investigators, at investigators
established in other research disciplines with expertise that may be applied
to digestive disease research, and, occasionally, at investigators already
working in digestive diseases who wish to make a substantial change in the
direction of their research. In addition, temporary salary support for one
Named New Investigator in a specified area of research with a defined P/F
study may be requested for up to 24 months. Subsequent individuals for this
position will be named by the Center Director and approved by the Center's
External Advisory Board and the NIDDK.
The Core Center grant may include limited funds for program enrichment such
as seminars, visiting scientists, consultants, and workshops.
MECHANISM OF SUPPORT
This RFA will use the NIH Core Center grant (P30) award mechanism. The
Principal Investigator is solely responsible for planning, directing, and
executing the proposed project. This RFA is a one-time solicitation. The
anticipated award dates are December 1, 2004 for four centers and March 1,
2005 for one center.
This RFA uses just-in-time concepts as well as a non-modular budgeting
format.
The receipt of five competing continuation applications is anticipated.
These continuation applications will compete with all other applications
received in response to this RFA.
FUNDS AVAILABLE
The NIDDK intends to commit approximately $6 million in FY 2005 to fund 5 new
and/or competing continuation applications in response to this RFA. An
applicant may request a project period of up to 5 years and a budget for
direct costs of up to $750,000 per year. Although the financial plans of the
NIDDK provide support for this program, awards pursuant to this RFA are
contingent upon the availability of funds and the receipt of a sufficient
number of meritorious applications.
ELIGIBLE INSTITUTIONS
You may submit an application if your institution has any of the following
characteristics:
o For-profit or non-profit organizations
o Public or private institutions, such as universities, colleges, hospitals,
and laboratories
o Units of State and local governments
o Eligible agencies of the Federal government
o Domestic institutions
Foreign institutions are not eligible to apply.
For the purpose of this RFA, the NIDDK will not support more than one DDRCC
center grant (P30) in an applicant institution. More details on the DDRCC
program are available in the SILVIO O. CONTE DIGESTIVE DISEASES RESEARCH CORE
CENTER GUIDELINES available on the Internet at
http://www.niddk.nih.gov/fund/other/centers/ddrcguidetoc.htm or from the
program director listed under WHERE TO SEND INQUIRIES, below.
INDIVIDUALS ELIGIBLE TO BECOME PRINCIPAL INVESTIGATORS
Any individual with the skills, knowledge, and resources necessary to carry
out the proposed research is invited to work with their institution to
develop an application for support. Individuals from underrepresented racial
and ethnic groups as well as individuals with disabilities always are
encouraged to apply for NIH programs.
SPECIAL REQUIREMENTS
o The DDRCC Director, who is the Principal Investigator on the P30 application
and Director of the Administrative Core, should be a scientist who can provide
effective administrative and scientific leadership. The Director will be
responsible for the organization and operation of the DDRCC and for
communication with the NIDDK on scientific and operational matters. Center
Directors are required, and their administrators are strongly encouraged, to
attend an annual meeting to be held at a location to be determined by the
NIDDK. Funds for travel to this meeting should be included in the budget for
the Administrative Core of the Center.
o Applications for DDRCC grants must propose a theme for the Center that is
relevant to digestive diseases research and supported by the research projects
comprising the research base for the DDRCC. The research base grants must be
summarized in accordance with the DDRCC guidelines found at
http://www.niddk.nih.gov/fund/other/centers/ddrcguidetoc.htm
o At least 50 percent of the already funded research base in a new
application must be supported by the NIDDK. In competing continuation
applications the percent may be less than 50 percent due to, for example, a
growing research base of investigators entering digestive diseases from other
fields. The initial review group will determine the significance of the
research base.
o Scientific personnel and institutional resources capable of supporting the
research base must be available. In addition, the institution and pertinent
departments must show a strong commitment to the Center's support. Such
commitment may be provided as dedicated space, staff recruitment, salary
support for investigators, dedicated equipment, or other financial support for
the proposed Center.
o Each core unit proposed for funding under the DDRCC must be utilized by a
minimum of three federally funded research projects. A detailed description of
each core unit proposed as part of the Center must be provided, with detailed
budget and budget justification. A core director must be named for each core
proposed. The description of each core unit proposed should include a
rationale, indicating how it will support the research effort in a cost-
effective manner. Facilities must be available for the primary needs of the
DDRCC Program because funds for new construction are not available.
o Promoting interdisciplinary collaboration among scientists working within a
Center is a major goal of the DDRCC Program. Each Center application should
describe how continuing and new interactions will be fostered and encouraged
by the DDRCC.
o Another goal of the DDRCC is to attract scientists to the field of digestive
diseases research. Therefore, both a Pilot and Feasibility (PF) program as
well as an Enrichment Program may be supported within the DDRCC program.
WHERE TO SEND INQUIRIES
We encourage inquiries concerning this RFA and welcome the opportunity to
answer questions from potential applicants. Inquiries may fall into three
areas: scientific/research, peer review, and financial or grants management
issues:
o Direct your questions about scientific/research issues to:
Judith Podskalny, Ph.D.
Program Director
Division of Digestive Diseases and Nutrition
National Institute of Diabetes and Digestive and Kidney Diseases
Two Democracy Plaza, Room 667
Bethesda, MD 20892-5450
Telephone: (301) 594-8876
Email: jp53s@nih.gov
o Direct your questions about peer review issues to:
Francisco O. Calvo, Ph.D.
Chief, Review Branch
Division of Extramural Activities
National Institute of Diabetes and Digestive and Kidney Diseases
Two Democracy Plaza, Room 752
Bethesda, MD 20892-5452
Telephone: (301) 594-8897
Email: fc15y@nih.gov
o Direct your questions about financial or grants management matters to:
Teresa Farris Marquette
Senior Grants Management Specialist
Division of Extramural Activities
National Institute of Diabetes and Digestive and Kidney Diseases
Two Democracy Plaza, Room 728
Bethesda, MD 20892-5456
Telephone: (301) 594-7682
Email: tm275a@nih.gov
LETTER OF INTENT
Prospective applicants are asked to submit a letter of intent that includes
the following information:
o Descriptive title of the proposed center
o Name, address, and telephone number of the Principal Investigator
o Names of other key personnel (Associate Directors, Core Directors)
o Participating institutions
o Number and title of this RFA
Although a letter of intent is not required, is not binding, and does not
enter into the review of a subsequent application, the information that it
contains allows IC staff to estimate the potential review workload and plan
the review.
The letter of intent is to be sent by the date listed at the beginning of
this document. The letter of intent should be sent to:
Francisco O. Calvo, Ph.D.
Chief, Review Branch
Division of Extramural Activities
National Institute of Diabetes and Digestive and Kidney Diseases
Two Democracy Plaza, Room 752
Bethesda, MD 20892-5452
Telephone: (301) 594-8897
Email: fc15y@nih.gov
SUBMITTING AN APPLICATION
Applications must be prepared using the PHS 398 research grant application
instructions and forms (rev. 5/2001). The PHS 398 is available at
https://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive
format. For further assistance contact GrantsInfo, Telephone (301) 710-0267,
Email: GrantsInfo@nih.gov.
SUPPLEMENTAL INSTRUCTIONS: The 'Silvio O. Conte Digestive Diseases Research
Core Center' guidelines provide more detailed information on the Centers and
on preparing the application. The guidelines are accessible at
http://www.niddk.nih.gov/fund/other/centers/ddrcguidetoc.htm.
USING THE RFA LABEL: The RFA label available in the PHS 398 (rev. 5/2001)
application form must be affixed to the bottom of the face page of the
application. Type the RFA number on the label. Failure to use this label
could result in delayed processing of the application such that it may not
reach the review committee in time for review. In addition, the RFA title
and number must be typed on line 2 of the face page of the application form
and the YES box must be marked. The RFA label is also available at:
https://grants.nih.gov/grants/funding/phs398/label-bk.pdf.
SENDING AN APPLICATION TO THE NIH: Submit a signed, typewritten original of
the application, including the Checklist, and three signed photocopies, in
one package to:
Center For Scientific Review
National Institutes Of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD 20892-7710
Bethesda, MD 20817 (for express/courier service)
At the time of submission, two additional copies of the application and all
appendices must be sent to:
Francisco O. Calvo, Ph.D.
Chief, Review Branch
Division of Extramural Activities
National Institute of Diabetes and Digestive and Kidney Diseases
Two Democracy Plaza, Room 752
Bethesda, MD 20892-5452
Telephone: (301) 594-8897
Email: fc15y@nih.gov
APPLICATION PROCESSING: Applications must be received by the application
receipt date listed in the heading of this RFA. If an application is
received after that date, it will be returned to the applicant without
review.
The Center for Scientific Review (CSR) will not accept any application in
response to this RFA that is essentially the same as one currently pending
initial review, unless the applicant withdraws the pending application.
However, when a previously unfunded application, originally submitted as an
investigator-initiated application, is to be submitted in response to an RFA,
it is to be prepared as a NEW application. That is the application for the
RFA must not include an Introduction describing the changes and improvements
made, and the text must not be marked to indicate the changes. While the
investigator may still benefit from the previous review, the RFA application
is not to state explicitly how.
PEER REVIEW PROCESS
Upon receipt, applications will be reviewed for completeness by the CSR and
for responsiveness to the RFA by the NIDDK. Incomplete and/or non-responsive
applications will be returned to the applicant without further consideration.
Applications that are complete and responsive to the RFA will be evaluated for
scientific and technical merit by an appropriate peer review group convened by
the NIDDK in accordance with the review criteria stated below. No site visits
are planned in the review of these applications; all information required for
evaluation must be contained in the application. As part of the initial merit
review, all applications will:
o Receive a written critique
o Undergo a process in which all applications will be discussed and assigned
a priority score
o Receive a second level review by the National Diabetes and Digestive and
Kidney Diseases Advisory Council.
REVIEW CRITERIA
All applications responding to this RFA will be evaluated according to the
review criteria as outlined in the SILVIO O. CONTE DIGESTIVE DISEASES RESEARCH
CORE CENTER GUIDELINES available on the Internet at
http://www.niddk.nih.gov/fund/other/centers/ddrcguidetoc.htm or from the
program director listed under WHERE TO SEND INQUIRIES, above.
As part of the initial scientific review, which will result in one overall
priority score for the P30 application, reviewers will rate each individual
research core and, if requested, the clinical component, as well as the P/F
program. The evaluation of the Enrichment Program will be reflected in the
adjectival score of the Administrative Core. The merit descriptors for each of
these components will appear in the summary statement. The review group will
assign a descriptor, rather than a score, for the research base, scientific
cores, the P/F program, and the Center Director.
Review Criteria
The most important component of a DDRCC is an ongoing, strong base of
digestive disease-related research.
Specific review criteria for Silvio O. Conte Digestive Diseases Research Core
Centers are:
o the scientific excellence of the Center's research base (its strengths,
its breadth and depth) as well as the relevance and interrelation of these
separately funded research projects to the central theme(s) or focus of the
Center and the likelihood for meaningful collaborations among Center
investigators. The existence of a base of established, independently
supported biomedical research of high quality is a prerequisite for the
establishment of a Silvio O. Conte Digestive Diseases Research Core Center
and is the most important component of the review. (The results of previous
peer reviews of its content will weigh heavily in the assessment of the
application's overall strength as a potential recipient of an award.)
o the qualifications, experience, and commitment of the Center investigators
responsible for the individual research projects, and their willingness to
interrelate with each other and contribute to the overall objectives of the
Silvio O. Contee Digestive Diseases Research Core Center.
o the appropriateness and relevance of the proposed Cores and their modes of
operation (such as how usage will be prioritized), facilities, and potential
for contribution to ongoing research. Competing continuation applications
must document the use, utility, quality control, and cost effectiveness of
each Core requested to continue as part of the Center. Progress will be
judged in part by the list of publications arising from the cores. At least
two users are required to establish a core. However, a greater number of
users will be considered to be more cost effective.
o for all applications, four P/F studies should be submitted for evaluation
as part of the review of the P/F program. In general for new applications,
the proposed P/F projects will be examined to assess the eligibility of the
P/F applicant and the adequacy of the selection process by which the
individual studies were selected. Applicants should refer to the
Administrative Guidelines for DDRCCs for specific details regarding the P/F
program and its review by the Scientific Review Group (SRG).
o the Named New Investigator, if requested, will be considered separately.
o the scientific and administrative leadership abilities of the proposed
Center Director and Associate Director and their commitment and ability to
devote adequate time to the effective management of the program.
o the administrative organization proposed for the following:
(a) Coordination of ongoing research between the separately funded projects
and the Center, including mechanisms for internal monitoring;
(b) Establishment and maintenance of internal communication and cooperation
among the Center investigators;
(c) Mechanism for selecting and replacing professional or technical personnel
within the Core Center;
(d) Mechanism for reviewing the use of and administration of funds for the
P/F program;
(e) Management capabilities that include fiscal administration, procurement,
property and personnel management, planning, budgeting, and other appropriate
capabilities;
o The institutional commitment to the program, including lines of
accountability regarding management of the Center grant and the institution's
contribution to the management capabilities of the Center;
o The academic environment and resources in which the activities will be
conducted, including the availability of space, equipment, facilities, and
the potential for interaction with scientists from other departments and
institutions;
o Efficient and effective use and/or planned use of the limited enrichment
funds, including the contribution of these activities in enhancing the
objectives of the Center;
o The appropriateness of the budgets for the proposed and approved work to
be done in Core facilities, for P/F studies (these are restricted funds and
are capped at $150,000), and for enrichment in relation to the total Center
program.
Total requested Direct Costs are limited to $750,000 (including the P/F
program). For competing continuation applications, total requested Direct
Costs should not exceed the $750,000 cap.
In addition to the criteria stated above, in accordance with NIH policy, all
applications will be reviewed with respect to the following:
o The adequacy of plans to include children, both genders, minorities, and
their subgroups, as appropriate for the scientific goals of the research.
Plans for the recruitment and retention of subjects will also be evaluated.
o The reasonableness of the proposed budget size and duration in relation to
the proposed DDRCC.
RECEIPT AND REVIEW SCHEDULE
Letter of Intent Receipt Date: October 16, 2003
Application Receipt Date: November 13, 2003
Peer Review Date: March 2004
Council Review: May 2004
Earliest Anticipated Start Date: December 2004
AWARD CRITERIA
Award criteria that will be used to make award decisions include:
o scientific merit (as determined by peer review)
o relevance to research areas of high programmatic interest to the Division of
Digestive Diseases and Nutrition, NIDDK and research areas targeted by
Congress;
o availability of funds
o geographic distribution
REQUIRED FEDERAL CITATIONS
MONITORING PLAN AND DATA AND SAFETY MONITORING BOARD: Research components
involving Phase I and II clinical trials must include provisions for
assessment of patient eligibility and status, rigorous data management,
quality assurance, and auditing procedures. In addition, it is NIH policy
that all clinical trials require data and safety monitoring, with the method
and degree of monitoring being commensurate with the risks (NIH Policy for
Data and Safety Monitoring, NIH Guide for Grants and Contracts, June 12, 1998:
https://grants.nih.gov/grants/guide/notice-files/not98-084.html).
INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH: It is the policy of
the NIH that women and members of minority groups and their sub-populations
must be included in all NIH-supported clinical research projects unless a
clear and compelling justification is provided indicating that inclusion is
inappropriate with respect to the health of the subjects or the purpose of the
research. This policy results from the NIH Revitalization Act of 1993 (Section
492B of Public Law 103-43).
All investigators proposing clinical research should read the "NIH Guidelines
for Inclusion of Women and Minorities as Subjects in Clinical Research -
Amended, October, 2001," published in the NIH Guide for Grants and Contracts
on October 9, 2001 (https://grants.nih.gov/grants/guide/notice-files/NOT-OD
-02-001.html); a complete copy of the updated Guidelines are available at
https://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_
2001.htm. The amended policy incorporates: the use of an NIH definition
of clinical research; updated racial and ethnic categories in compliance with
the new OMB standards; clarification of language governing NIH-defined Phase
III clinical trials consistent with the new PHS Form 398; and updated roles
and responsibilities of NIH staff and the extramural community. The policy
continues to require for all NIH-defined Phase III clinical trials that: a)
all applications or proposals and/or protocols must provide a description of
plans to conduct analyses, as appropriate, to address differences by
sex/gender and/or racial/ethnic groups, including subgroups if applicable;
and b) investigators must report annual accrual and progress in conducting
analyses, as appropriate, by sex/gender and/or racial/ethnic group
differences.
INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS:
The NIH maintains a policy that children (i.e., individuals under the age of
21) must be included in all human subjects research, conducted or supported by
the NIH, unless there are scientific and ethical reasons not to include them.
This policy applies to all initial (Type 1) applications submitted for receipt
dates after October 1, 1998.
All investigators proposing research involving human subjects should read the
"NIH Policy and Guidelines" on the inclusion of children as participants in
research involving human subjects that is available at
https://grants.nih.gov/grants/funding/children/children.htm.
REQUIRED EDUCATION ON THE PROTECTION OF HUMAN SUBJECT PARTICIPANTS: NIH policy
requires education on the protection of human subject participants for all
investigators submitting NIH proposals for research involving human subjects.
You will find this policy announcement in the NIH Guide for Grants and
Contracts Announcement, dated June 5, 2000, at
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html.
HUMAN EMBRYONIC STEM CELLS (hESC): Criteria for federal funding of research on
hESCs can be found at https://grants.nih.gov/grants/stem_cells.htm and at
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html. Only
research using hESC lines that are registered in the Human Embryonic Stem Cell
Registry will be eligible for federal funding (see http://escr.nih.gov). It is
the responsibility of the applicant to provide the official NIH identifier(s)
for the hESC line(s) to be used in the proposed research. Applications that do
not provide this information will be returned without review.
Because P30 funds do not directly support research projects, the issues of
minority/gender representation, inclusion of children as participants in
research involving human subjects, required education on the protection of
human subject participants, and the use of human embryonic stem cells will
have been addressed at the individual project level (i.e., R01 level).
However, the application must specifically address these issues for any P/F
projects or cores as appropriate.
PUBLIC ACCESS TO RESEARCH DATA THROUGH THE FREEDOM OF INFORMATION ACT: The
Office of Management and Budget (OMB) Circular A-110 has been revised to
provide public access to research data through the Freedom of Information Act
(FOIA) under some circumstances. Data that are (1) first produced in a
project that is supported in whole or in part with Federal funds and (2) cited
publicly and officially by a Federal agency in support of an action that has
the force and effect of law (i.e., a regulation) may be accessed through FOIA.
It is important for applicants to understand the basic scope of this
amendment. NIH has provided guidance at
https://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm.
Applicants may wish to place data collected under this RFA in a public
archive, which can provide protections for the data and manage the
distribution for an indefinite period of time. If so, the application should
include a description of the archiving plan in the study design and include
information about this in the budget justification section of the
application. In addition, applicants should think about how to structure
informed consent statements and other human subjects procedures given the
potential for wider use of data collected under this award.
STANDARDS FOR PRIVACY OF INDIVIDUALLY IDENTIFIABLE HEALTH INFORMATION: The
Department of Health and Human Services (DHHS) issued final modification to
the "Standards for Privacy of Individually Identifiable Health Information",
the "Privacy Rule," on August 14, 2002. The Privacy Rule is a federal
regulation under the Health Insurance Portability and Accountability Act
(HIPAA) of 1996 that governs the protection of individually identifiable
health information, and is administered and enforced by the DHHS Office for
Civil Rights (OCR). Those who must comply with the Privacy Rule (classified
under the Rule as "covered entities") must do so by April 14, 2003 (with the
exception of small health plans which have an extra year to comply).
Decisions about applicability and implementation of the Privacy Rule reside
with the researcher and his/her institution. The OCR website
(http://www.hhs.gov/ocr/) provides information on the Privacy Rule, including
a complete Regulation Text and a set of decision tools on "Am I a covered
entity?" Information on the impact of the HIPAA Privacy Rule on NIH
processes involving the review, funding, and progress monitoring of grants,
cooperative agreements, and research contracts can be found at
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-025.html.
URLs IN NIH GRANT APPLICATIONS OR APPENDICES: All applications and proposals
for NIH funding must be self-contained within specified page limitations.
Unless otherwise specified in an NIH solicitation, Internet addresses (URLs)
should not be used to provide information necessary to the review because
reviewers are under no obligation to view the Internet sites. Furthermore,
we caution reviewers that their anonymity may be compromised when they
directly access an Internet site.
HEALTHY PEOPLE 2010: The Public Health Service (PHS) is committed to achieving
the health promotion and disease prevention objectives of "Healthy People
2010," a PHS-led national activity for setting priority areas. This RFA is
related to one or more of the priority areas. Potential applicants may obtain
a copy of "Healthy People 2010" at http://www.health.gov/healthypeople.
AUTHORITY AND REGULATIONS: This program is described in the Catalog of
Federal Domestic Assistance at http://www.cfda.gov/ and is not subject to the
intergovernmental review requirements of Executive Order 12372 or Health
Systems Agency review. Awards are made under the authorization of Sections
301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284)
and under Federal Regulations 42 CFR 52 and 45 CFR Parts 74 and 92. All
awards are subject to the terms and conditions, cost principles, and other
considerations described in the NIH Grants Policy Statement. The NIH Grants
Policy Statement can be found at
https://grants.nih.gov/grants/policy/policy.htm
The PHS strongly encourages all grant recipients to provide a smoke-free
workplace and discourage the use of all tobacco products. In addition,
Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in
certain facilities (or in some cases, any portion of a facility) in which
regular or routine education, library, day care, health care, or early
childhood development services are provided to children. This is consistent
with the PHS mission to protect and advance the physical and mental health of
the American people.